FDA approval of controversial Alzheimer's drug could delay discovery of more promising treatments
By Étienne Aumont, Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
Marc-André Bédard, Professor of cognitive pharmacology, Université du Québec à Montréal (UQAM)
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
Read complete article
© The Conversation
- Tuesday, June 15, 2021